Daxor Corporation (DXR)
| Bid | 7 |
| Market Cap | 37.58M |
| Revenue (ttm) | 154.2K |
| Net Income (ttm) | 1.69M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -86.33 |
| Forward PE | 52 |
| Analyst | Strong Buy |
| Ask | 8.15 |
| Volume | 200 |
| Avg. Volume (20D) | 7,116 |
| Open | 7.77 |
| Previous Close | 7.52 |
| Day's Range | 7.77 - 7.77 |
| 52-Week Range | 6.55 - 10.00 |
| Beta | -0.06 |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 221.75% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
TruLite Health Bolsters Health Equity Expertise with Expanded Leadership TeamTEMPE, Ariz.--(BUSINESS WIRE)--TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intellige...